Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Voyager Therapeutics, Inc. filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing neurotherapeutics for central nervous system diseases. Its Form 8-K reports include quarterly and annual financial results, corporate updates, Regulation FD investor presentations, executive officer transitions and related exhibits covering pipeline and platform information.
Proxy materials describe annual meeting matters such as director elections, advisory executive compensation votes, auditor ratification, charter matters and proposals involving authorized capital. The filing record also identifies Voyager’s common stock, par value and Nasdaq Global Select Market listing, and formalizes governance and capitalization disclosures relevant to its public-company status.
Voyager Digital affiliate reported transactions of Common stock in a Form 144 notice. The filing shows a sale of 12,192 shares on 02/10/2026 with proceeds of $46,093.08. The notice also lists 11,732 shares tied to restricted stock vesting dated 02/17/2026.
Voyager Therapeutics submitted a Form 144 notice disclosing a proposed sale of 3,301 common shares. The filing identifies the shares as Restricted Stock Vesting tied to compensation with a vesting date of 02/17/2026. The filing also records a prior sale by Todd Carter of 3,525 common shares on 02/10/2026. The Form lists 02/18/2026 and notes the securities trade on NASDAQ.
VYGR submitted a Rule 144 notice for the sale of 3,882 shares of its common stock tied to restricted stock vesting on 02/17/2026. The filing also lists a prior sale of 4,569 common shares on 02/10/2026 reported by Robin E. Swartz.
Voyager Therapeutics ownership disclosure: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 4,000,000 common shares, representing 7.19% of the class as of 12/31/2025. The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that Armistice exercises voting and investment power over the Master Fund's holdings. The Master Fund disclaims beneficial ownership by reason of its inability to vote or dispose of the shares under its Investment Management Agreement with Armistice Capital.
EcoR1 Capital and affiliates reported a sizable ownership position in Voyager Therapeutics, Inc. common stock. EcoR1 Capital, LLC and its control person Oleg Nodelman each beneficially own 4,002,847 shares, representing 6.8% of Voyager’s common stock. EcoR1 Capital Fund Qualified, L.P. directly holds 3,756,988 shares, or 6.4% of the class.
The filing shows no sole voting or dispositive power; all authority is shared among the reporting persons. They state the shares were acquired and are held in the ordinary course of business and not for the purpose, or with the effect, of changing or influencing control of Voyager Therapeutics.
Voyager Therapeutics, Inc. announced that Chief Medical Officer Toby Ferguson, M.D., Ph.D. has decided to resign from his role and all other positions with the company and its subsidiaries, effective February 20, 2026, to pursue a new opportunity.
The company states that Dr. Ferguson’s resignation is not due to any disagreement with Voyager. President and Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D. has agreed to assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis after the resignation becomes effective.
Swartz Robin reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 4,569 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 210,078 shares.
Sandrock Alfred reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 12,192 shares at a weighted average price of $3.78 per share. Following the reported transactions, holdings were 509,989 shares.
Carter Todd Alfred reported open-market sale transactions in a Form 4 filing for VYGR. The filing lists transactions totaling 3,525 shares at a weighted average price of $3.85 per share. Following the reported transactions, holdings were 153,193 shares.
Voyager Therapeutics Chief Medical Officer receives new equity awards. On February 6, 2026, Toby Ferguson was granted 45,000 restricted stock units (RSUs) and a stock option for 210,000 shares of common stock at an exercise price of $3.68 per share.
The RSUs vest over three years, in three equal annual installments starting one year after the grant date, subject to continued service. The stock option vests over four years, with 1/48th of the shares vesting monthly after the first month, also conditioned on continued service. Following the RSU grant, Ferguson directly beneficially owns 183,914 shares of common stock.